|Patricia Thompson, MD, PhD
Professor of Pathology
Interim Program Leader for Imaging, Bioinformatics and Engineering Science
Deputy Director Stony Brook Cancer Center
Sulindac, a non-steroidal anti-inflammatory drug, reduces breast
density and alters collagen alignment in breast tissue.
Wednesday, September 5, 2018 3pm—4pm
Atkins Center – HSC Level 4 (Radiology)
Non-steroidal anti-inflammatory agents like aspirin and the non-selective cyclooxygenase inhibitor
sulindac have been shown in preclinical experimental models to prevent the development of epi-
thelial tumorigenesis. Results of an interim analysis of a Phase II biomarker clinical study of sulindac
150 mg twice daily for 12 months compared to no treatment control on change in breast density, a
intermediate biomarker of breast cancer risk, will be presented. Results for effects of sulindac on
tissue collagen alignment and collagen fiber type will be discussed along with plans for novel mi-
croscopy work of collagen in breast tissue as a biomarker of risk.
1) Describe the effects of non-steroidal anti-inflammatory agents as cancer chemoprevention
agents for breast and other cancers.
2) Explain the relationship between breast density and breast cancer risk.
3) Relate the effects of cancer prevention agents on breast density to their relationship to breast
4) Discuss the role of the tissue microenvironment as a drug target for cancer prevention.
*** CME CREDIT AVAILABLE ***
Questions? Please call the Biomedical Informatics Department at 631-638-2590.